Many autistic people also have Attention-Deficit/Hyperactivity Disorder, often referred to as ADHD. Some people use the term AuDHD to describe this combined profile.
For autistic people with ADHD, ADHD medication may reduce ADHD symptoms such as inattention, impulsivity, hyperactivity, and difficulty sustaining or shifting attention. For some people, this can also indirectly reduce distress, anxiety, overwhelm, or daily functional load because life feels more manageable.
The treatment target is ADHD symptoms, not autistic characteristics. Medication decisions should focus on whether the person experiences meaningful benefit without increased distress, reduced wellbeing, or loss of sense of self.
Responses to ADHD medication are highly individual. Some autistic people with ADHD find medication life-changing. Others experience side effects, emotional blunting, increased anxiety, appetite changes, sleep disruption, or sensory discomfort that outweigh the benefits.
This blog provides general information only and is not a substitute for individual medical advice from a qualified prescriber.
Common ADHD medications include stimulant and non-stimulant options, such as:
The most appropriate medication depends on the person’s age, ADHD profile, anxiety level, sleep, appetite, sensory profile, medical history, co-occurring conditions, and previous medication responses.
In Australia, prescribing rules, availability, and Pharmaceutical Benefits Scheme subsidy arrangements vary across jurisdictions and clinical contexts. Assessment and prescribing are usually managed by a psychiatrist, paediatrician, or another appropriately authorised prescriber, with some prescribing arrangements changing over time across states and territories.
ADHD medications, particularly stimulants, may help some people with:
For some autistic people with ADHD, this can reduce the mental exhaustion involved in trying to organise thoughts, remember steps, complete tasks, and manage competing demands.
Some autistic people with ADHD describe:
Emotional regulation is shaped by many factors, including sensory load, communication demands, anxiety, trauma history, environmental mismatch, sleep, pain, and exhaustion. When ADHD symptoms such as impulsivity, restlessness, or rapid escalation of distress are reduced, some people may feel more able to pause, reflect, and respond in ways that align with their intentions.
Many AuDHD adults describe their ADHD as involving constant mental noise, racing thoughts, competing priorities, or difficulty choosing where to start.
When medication is effective, some people report:
For some people, this may indirectly reduce anxiety because daily life becomes more predictable and manageable. For others, medication can increase anxiety or make the person feel too alert, tense, or overstimulated. This is why careful monitoring is important.
When ADHD medication is helpful and well tolerated, some people may find it easier to:
These changes can support confidence and autonomy, especially when medication is combined with appropriate environmental and relational supports.
Unsupported ADHD can contribute to chronic stress, shame, low self-esteem, anxiety, depression, burnout, and repeated experiences of misunderstanding. When ADHD symptoms are better supported, some people may experience less functional overload and improved wellbeing. However, medication should not be presented as a direct treatment for depression, anxiety, burnout, trauma, or sensory distress, which require assessment and support in their own right.
Some autistic people appear to be more sensitive to the subjective effects of medication. This may include increased awareness of:
A dose that is suitable for one person may feel overwhelming for another. Some people benefit from very small dose adjustments and slower titration.
For some people, medication may reduce anxiety because ADHD-related cognitive load is lower. When thoughts feel clearer, tasks are easier to start, and daily demands feel more manageable, the person may experience less stress and overwhelm.
For others who already experience significant anxiety, hypervigilance, sensory overload, panic, or trauma-related arousal, ADHD medication may sometimes intensify those experiences.
Some people describe feeling:
Both patterns are possible.
Appetite and sleep effects are especially important for autistic people who already have:
Changes in appetite or sleep can affect mood, emotional regulation, sensory tolerance, and daily functioning. These effects should be monitored carefully.
Some AuDHD people describe feeling calmer and more able to be themselves when medication is effective. Others describe feeling:
Subjective experience is clinically important and should guide medication decisions. The best medication and dose should support functioning without making the person feel distressed, diminished, or disconnected from themselves.
ADHD medication may improve ADHD symptoms such as attention, impulsivity, restlessness, and task persistence. It is not expected to directly alter autism-related differences such as:
If distress continues despite ADHD medication, this should prompt broader review rather than a narrow focus on dose. Sensory demands, communication expectations, workload, sleep, pain, anxiety, trauma history, and available supports may all affect participation, recovery, and daily functioning.
People who are autistic and have ADHD often benefit from an individualised, carefully monitored approach that considers both benefits and side effects. This may include:
Physical monitoring is also important and may include weight, appetite, pulse, blood pressure, cardiovascular history, and other health factors identified by the prescriber. Monitoring should be guided by an appropriately qualified clinician.
Medication decisions should consider whether the medication:
Medication may support some ADHD-related needs, but daily supports remain central. Many autistic people with ADHD also benefit from:
These supports are often central to whether medication is helpful, tolerable, and meaningful in everyday life.
Research suggests that some ADHD medications can reduce ADHD symptoms in autistic children and adolescents, particularly hyperactivity, impulsivity, and inattention. Evidence for adults, long-term outcomes, and broader effects on wellbeing, anxiety, burnout, sensory overload, or quality of life is more limited.
This means that medication decisions should be based on careful clinical assessment, current evidence, individual goals, and ongoing monitoring rather than assumptions that medication will help or harm all autistic people with ADHD in the same way.
ADHD medication can be very helpful for some autistic people with ADHD, especially when ADHD symptoms are contributing to exhaustion, disorganisation, impulsivity, emotional escalation, or difficulty managing daily demands. For others, side effects, anxiety, appetite changes, sleep disruption, sensory discomfort, or emotional blunting may outweigh the benefits.
Responses are highly individual. Finding the right medication, dose, and support plan may take time and should be guided by a clinician who understands both autism and ADHD. The goal is to support attention, regulation, autonomy, wellbeing, and quality of life while respecting the person’s autistic characteristics, subjective experience, and sense of self.
We recommend the upcoming webcast on autism, ADHD and executive function, presented by Prof. Tony Attwood and Dr. Michelle Garnett.
Autism, ADHD and Executive Function (17th July 2026) is designed for autistic people aged 14 and over, parents and carers, health and education professionals, and employers. Research over several decades has shown that it is very common for autistic individuals to also have ADHD, with some studies estimating the co-occurrence is up to 70%. Even when the full diagnostic criteria for ADHD are not met, many people experience daily difficulties with focus, concentration, planning, organisation, time management, impulsivity and completing tasks. This full-day course covers the latest research on autism and ADHD, the additional strengths and challenges of being both, and strategies to cope across school, work, leisure and home. AuDHD across the age span is covered, including the pros and cons of medication for each neurotype, how to support a student with ADHD or executive function difficulties, and how neurodivergence in the family affects relationships and parenting.
The webcast runs 9:30am to 4:00pm AEST (Brisbane) and includes 5.5 hours of live training, live Q&A with Tony and Michelle, downloadable handouts, 60 days of recording access, CPD hours, and a Certificate of Attendance.
Antshel, K. M., Hargrave, T. M., Simonescu, M., Kaul, P., Hendricks, K., & Faraone, S. V. (2011). Advances in understanding and treating ADHD. BMC Medicine, 9(1). https://doi.org/10.1186/1741-7015-9-72
Australian ADHD Professionals Association. (2022). Australian evidence-based clinical guideline for attention deficit hyperactivity disorder. AADPA.
Bratt, A. M., Masanyero-Bennie, B., & Kelley, S. P. (2017). A meta-analysis of the efficacy of immediate release methylphenidate to reduce hyperactivity in children with autistic spectrum disorder. J Pharm Sci Exp Pharmacol, 1(1), 11-20. https://doi.org/10.29199/jpct.101014
Martins, P. L. B., Torquato, G. C. P., Dias, G. A. P. F., Leite, I. B., Gaspar, T. M., Pinto, J. P., & Macedo, D. S. (2024). Effectiveness of pharmacological interventions for managing ADHD symptoms in individuals with autism spectrum disorder: a systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 134, 111089.
National Institute for Health and Care Excellence. (2018, updated 2025). Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline NG87.
Sturman, N., Deckx, L., & van Driel, M. L. (2017). Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database of Systematic Reviews.
Suetani S, Hull J, Scott JG. Pharmacological management of attention deficit hyperactivity disorder in adults. Aust Prescr. 2026 Feb;49(1):10-15. doi: 10.18773/austprescr.2026.002.
Rodrigues, R., Lai, M.-C., Beswick, A., Gorman, D.A., Anagnostou, E., Szatmari, P., Anderson, K.K. and Ameis, S.H. (2021), Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. J. Child Psychol. Psychiatr., 62: 680-700. https://doi.org/10.1111/jcpp.13305
Tomiyama, S., Yoshida, K., Tani, H., & Uchida, H. (2025). Pharmacological treatment of autism spectrum disorder: A systematic review of treatment guidelines. Pharmacopsychiatry, 58(03), 100–116. https://doi.org/10.1055/a-2514-4452
